Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1995 May 15;308(Pt 1):275–281. doi: 10.1042/bj3080275

Detection and analysis of agonist-induced formation of the complex of the stimulatory guanine nucleotide-binding protein with adenylate cyclase in intact wild-type and beta 2-adrenoceptor-expressing NG108-15 cells.

G D Kim 1, I C Carr 1, G Milligan 1
PMCID: PMC1136873  PMID: 7538756

Abstract

Neuroblastoma x glioma hybrid, NG108-15, cells appear to express the alpha-subunit of the guanine nucleotide-binding protein Gs in a substantial molar excess over its effector adenylate cyclase [Kim, Adie and Milligan (1994) Eur. J. Biochem. 219, 135-143]. Addition of the IP prostanoid receptor agonist iloprost to intact NG108-15 cells resulted in a dose-dependent increase in formation of the complex between Gs alpha and adenylate cyclase (GSAC) as measured by specific high-affinity binding of [3H]forskolin. NG108-15 cells transfected to express either relatively high (clone beta N22) or low (clone beta N17) levels of beta 2-adrenoceptor both showed dose-dependent increases in specific [3H]forskolin binding in response to the beta-adrenoceptor agonist isoprenaline, and maximally effective concentrations of isoprenaline resulted in the generation of similar numbers of GSAC complexes in both clones. The dose-effect curve for clone beta N22, however, was some 15-fold to the left of that for clone beta N17, which is similar to that noted for isoprenaline-mediated stimulation of adenylate cyclase activity [Adie and Milligan (1994) Biochem. J. 303, 803-808]. In contrast, dose-effect curves for iloprost stimulation of [3H]forskolin binding were not different in clones beta N22 and beta N17. Basal specific [3H]forskolin binding in the absence of agonist was significantly greater in cells of clone beta N22 than clone beta N17. This was not a reflection of higher immunological levels of adenylate cyclase, indicating that the higher basal formation of GSAC probably reflects empty-receptor activation of Gs. This higher basal specific [3H]forskolin binding was partially reversed by propranolol. The addition of the opioid peptide D-Ala-D-Leu-enkephalin to NG108-15 cells did not reduce iloprost-stimulated [3H]forskolin binding even though this peptide inhibits stimulated adenylate cyclase activity by activation of a delta opioid receptor.

Full text

PDF
275

Images in this article

279Figure 6
on p.279

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adie E. J., Milligan G. Agonist regulation of cellular Gs alpha-subunit levels in neuroblastoma x glioma hybrid NG108-15 cells transfected to express different levels of the human beta 2 adrenoceptor. Biochem J. 1994 Jun 15;300(Pt 3):709–715. doi: 10.1042/bj3000709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adie E. J., Milligan G. Agonist regulation of cellular levels of the stimulatory guanine nucleotide-binding protein, Gs, in wild type and transfected neuroblastoma-glioma hybrid NG108-15 cells. Biochem Soc Trans. 1993 May;21(2):432–435. doi: 10.1042/bst0210432. [DOI] [PubMed] [Google Scholar]
  3. Adie E. J., Milligan G. Regulation of basal adenylate cyclase activity in neuroblastoma x glioma hybrid, NG108-15, cells transfected to express the human beta 2 adrenoceptor: evidence for empty receptor stimulation of the adenylate cyclase cascade. Biochem J. 1994 Nov 1;303(Pt 3):803–808. doi: 10.1042/bj3030803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Adie E. J., Mullaney I., McKenzie F. R., Milligan G. Concurrent down-regulation of IP prostanoid receptors and the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs) during prolonged exposure of neuroblastoma x glioma cells to prostanoid agonists. Quantification and functional implications. Biochem J. 1992 Jul 15;285(Pt 2):529–536. doi: 10.1042/bj2850529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Alousi A. A., Jasper J. R., Insel P. A., Motulsky H. J. Stoichiometry of receptor-Gs-adenylate cyclase interactions. FASEB J. 1991 Jun;5(9):2300–2303. doi: 10.1096/fasebj.5.9.1650314. [DOI] [PubMed] [Google Scholar]
  6. Chidiac P., Hebert T. E., Valiquette M., Dennis M., Bouvier M. Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol. 1994 Mar;45(3):490–499. [PubMed] [Google Scholar]
  7. DeBlasi A., O'Reilly K., Motulsky H. J. Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci. 1989 Jun;10(6):227–229. doi: 10.1016/0165-6147(89)90266-6. [DOI] [PubMed] [Google Scholar]
  8. Gunning P., Leavitt J., Muscat G., Ng S. Y., Kedes L. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. Proc Natl Acad Sci U S A. 1987 Jul;84(14):4831–4835. doi: 10.1073/pnas.84.14.4831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hamprecht B., Glaser T., Reiser G., Bayer E., Propst F. Culture and characteristics of hormone-responsive neuroblastoma X glioma hybrid cells. Methods Enzymol. 1985;109:316–341. doi: 10.1016/0076-6879(85)09096-6. [DOI] [PubMed] [Google Scholar]
  10. Kim G. D., Adie E. J., Milligan G. Quantitative stoichiometry of the proteins of the stimulatory arm of the adenylyl cyclase cascade in neuroblastoma x glioma hybrid, NG108-15 cells. Eur J Biochem. 1994 Jan 15;219(1-2):135–143. doi: 10.1111/j.1432-1033.1994.tb19923.x. [DOI] [PubMed] [Google Scholar]
  11. Laurenza A., Seamon K. B. High-affinity binding sites for [3H]forskolin. Methods Enzymol. 1991;195:52–65. doi: 10.1016/0076-6879(91)95154-c. [DOI] [PubMed] [Google Scholar]
  12. Laurenza A., Sutkowski E. M., Seamon K. B. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? Trends Pharmacol Sci. 1989 Nov;10(11):442–447. doi: 10.1016/S0165-6147(89)80008-2. [DOI] [PubMed] [Google Scholar]
  13. Levitzki A., Marbach I., Bar-Sinai A. The signal transduction between beta-receptors and adenylyl cyclase. Life Sci. 1993;52(26):2093–2100. doi: 10.1016/0024-3205(93)90724-h. [DOI] [PubMed] [Google Scholar]
  14. Marbach I., Bar-Sinai A., Minich M., Levitzki A. Beta subunit copurifies with GppNHp-activated adenylyl cyclase. J Biol Chem. 1990 Jun 15;265(17):9999–10004. [PubMed] [Google Scholar]
  15. McKenzie F. R., Milligan G. Delta-opioid-receptor-mediated inhibition of adenylate cyclase is transduced specifically by the guanine-nucleotide-binding protein Gi2. Biochem J. 1990 Apr 15;267(2):391–398. doi: 10.1042/bj2670391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McKenzie F. R., Milligan G. Prostaglandin E1-mediated, cyclic AMP-independent, down-regulation of Gs alpha in neuroblastoma x glioma hybrid cells. J Biol Chem. 1990 Oct 5;265(28):17084–17093. [PubMed] [Google Scholar]
  17. Milano C. A., Allen L. F., Rockman H. A., Dolber P. C., McMinn T. R., Chien K. R., Johnson T. D., Bond R. A., Lefkowitz R. J. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science. 1994 Apr 22;264(5158):582–586. doi: 10.1126/science.8160017. [DOI] [PubMed] [Google Scholar]
  18. Milligan G. Foetal-calf serum stimulates a pertussis-toxin-sensitive high-affinity GTPase activity in rat glioma C6 BU1 cells. Biochem J. 1987 Jul 15;245(2):501–505. doi: 10.1042/bj2450501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Morris D., McHugh-Sutkowski E., Moos M., Jr, Simonds W. F., Spiegel A. M., Seamon K. B. Immunoprecipitation of adenylate cyclase with an antibody to a carboxyl-terminal peptide from Gs alpha. Biochemistry. 1990 Sep 25;29(38):9079–9084. doi: 10.1021/bi00490a027. [DOI] [PubMed] [Google Scholar]
  20. Pfeuffer E., Dreher R. M., Metzger H., Pfeuffer T. Catalytic unit of adenlyate cyclase: purification and identification by affinity crosslinking. Proc Natl Acad Sci U S A. 1985 May;82(10):3086–3090. doi: 10.1073/pnas.82.10.3086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Samama P., Pei G., Costa T., Cotecchia S., Lefkowitz R. J. Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. Mol Pharmacol. 1994 Mar;45(3):390–394. [PubMed] [Google Scholar]
  22. Schütz W., Freissmuth M. Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol Sci. 1992 Oct;13(10):376–380. doi: 10.1016/0165-6147(92)90116-n. [DOI] [PubMed] [Google Scholar]
  23. Smigel M. D. Purification of the catalyst of adenylate cyclase. J Biol Chem. 1986 Feb 5;261(4):1976–1982. [PubMed] [Google Scholar]
  24. Tang W. J., Gilman A. G. Adenylyl cyclases. Cell. 1992 Sep 18;70(6):869–872. doi: 10.1016/0092-8674(92)90236-6. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES